|Bid||164.66 x 900|
|Ask||170.16 x 800|
|Day's Range||167.91 - 171.92|
|52 Week Range||90.14 - 196.00|
|Beta (3Y Monthly)||2.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||223.58|
It’s not often you get to witness the opening of a whole new market sector. After last year’s move by the Canadian Parliament to fully legalize marijuana and cannabis products throughout the country, and the increasing numbers of American states south of the border pursuing similar legalization policies, we are seeing just that. As Giadha Aquirre de Carcer, CEO of New Frontier Data, put it in a report on the worldwide cannabis market, “The legal cannabis industry has truly gone global; even in the face of extensive prohibition, cannabis consumption grows, and attitudes and challenging perceptions about the typical cannabis user continue to shift.”It’s an exciting time, one that is also opening new pathways for investment. In this article, we’ll dip into the TipRanks database to look at four companies that have generated headlines in recent months. All four are well on the way to establishing themselves as players in the cannabis sector, but each one is following a separate path to success. Aurora Cannabis, Inc. (TSE:ACB)Aurora is staking its future on size, positioning itself as the world’s largest supplier of cannabis products to the medical market. And large is definitely the right word – Aurora’s current production stands at more than 25 metric tons per quarter, and is on track to exceed 600 tons annually by the end of 2020.The company’s scale has brought Aurora both benefits and costs. On the positive side, Aurora gains economies of scale. High-volume production provides a higher revenue stream, and open doors to bulk customers that are unavailable to smaller producers. This was clear in last month’s quarterly report, which showed a 367% year-over-year gross revenue increase, and a 99% quarter-over-quarter increase in production. The cost to the company was clear, however. Aurora reported a loss of $158.4 million Canadian, coming out to 16 cents per share.The operating loss, despite the production and revenue increases, stems from the company’s heavy investments in increased acreage and growing facilities. Management expects that the benefits of those investment – in higher production and lower costs per unit sold – will outweigh the costs and begin generating positive earnings by Q4.Early last month, five-star analyst Martin Landry (Track Record & Ratings), GMP FirstEnergy’s expert on the consumer health sector, weighed in on Aurora, saying, “Data tracking dried flower inventory availability for online recreational cannabis stores in Ontario, Quebec and Alberta, or about 73% of the Canadian population, found that Aurora has been best performer with a more than 25% share of in-stock SKUs since the start of the year.” Landry expects that Aurora will become the industry leader, building on that strong presence. He gives the company a price target of $15 Canadian, suggesting an upside of 48%.Overall, Aurora gets a ‘Strong Buy’ from the analyst consensus, based on 6 buys and 1 hold given over the past three months. The company’s average price target, $14.33 Canadian, and current share price, $10.13 Canadian, give an upside potential of 41%.View TSE:ACB Price Target & Analyst Ratings Detail Canopy Growth (TSE:WEED)Like Aurora, Canopy is a giant in the cannabis industry. By market cap, it’s the largest company in the sector, and has the second highest production – a reversal of Aurora’s numbers. And while Aurora is positioning itself to supply the medical market, Canopy has put itself squarely in the recreational segment of the cannabis field. In a widely publicized move at the end of last year, Canopy was partially acquired by Constellation Brands (STZ), the alcohol giant that owns two of Mexico’s largest beer brands.Canopy is also investing heavily in future production and the American market; the company is scheduled to approve an acquisition deal with US grower Acreage on June 19. The move, in which Canopy will put down $300 million for rights to finish the purchase “if and when” the US Federal government legalizes marijuana nationally. The move will give Canopy an ‘in’ for the US market, when restrictions on interstate trade are lifted.Looking at the two acquisition plans together, it’s clear that Canopy is eyeing the American recreational cannabis market. Even if the Federal government does not legalize marijuana any time soon (putting the Acreage deal on hold), Canopy’s partnership with Constellation Brands gives it a chance to develop cannabis infused beverages with a line on distribution networks in the US and worldwide.Writing from Alliance Global Partners, Aaron Grey (Track Record & Ratings) points out that Canopy’s Acreage deal, should it be approved, will position Canopy to take the lead in the US cannabis market, the world’s largest. He also points out the importance of the company’s profitable base in Canada’s recreational market: “[While we do] not foresee Canopy being profitable until FY21, expect the company to be profitable in the Canadian cannabis market as it continues with its international expansion.”Canopy’s size – in production and market cap – along with its profitable Canadian base business, underlies its "Moderate Buy’ analyst consensus rating. In the last three months, Canopy has received 6 buy ratings and 4 holds. WEED shares sell in Toronto for $55 Canadian; the average price target of $80 Canadian gives the stock a 45% upside potential.View TSE:WEED Price Target & Analyst Ratings Detail Charlotte’s Web Holdings (TSE:CWEB)The US state of Colorado has been a leader in the cannabis legalization movement, making it a natural home for US cannabis companies. Based in the city of Boulder, Charlotte’s Web recently up listed to the Toronto Stock Exchange, making it the first American cannabis company to do so. The company’s niche – hemp-based cannabidiol (CBD) extracts and products – while not fully legal under US Federal law, is more widely accepted at the state level than THC-derived cannabis products and can be sold online in the United States.CBD products, in both the consumer health and prescription markets, are growing increasing popular in the US. Charlotte’s Web has capitalized on that, and now has a presence in over 6,000 retail locations around the country, and is seeing increasing business online. In response to increasing demand, the company has ramped up its production capabilities, and is now growing on double its 2018 acreage. Management expects to produce in excess of 500 metric tons of hemp and hemp products this year, and predicts that revenue will double to $145 US.Charlotte Web’s greatest advantage, however, is not the popularity of its product or the increasing demand and production. Rather, it’s that the company is already profitable. After its IPO in 2018, the company generated earnings of 16 cents per share, and that number is expected to hit 33 cents this year and 75 cents in 2020.Jason Zandberg (Track Record & Ratings), five-star analyst with PI Financial, notes all of this in his recent review of CWEB stock. He points out, “CWEB has now shipped first orders to three national brand supermarket/grocery and drugstore retailers in select states, with shipments to a fourth commencing post-Q1. Also, e-commerce sales, which accounted for 49 per cent of total sales in the quarter, grew by 60 per cent year-over-year…”Zandberg sees CWEB generating 2019 revenues of $142.9 million, in line with the company’s guidance, and predicts that 2020 revenues will exceed $300 million. Building on these upbeat forecasts, he sets a price target of $30 Canadian for CWEB shares, suggesting an upside of 102%. His target for the stock is only slightly more optimistic than the conventional wisdom. The average price target on CWEB in Toronto is $29.50 Canadian; with a share price of $14, this gives the stock a 98% potential upside. The analyst consensus, a ‘Moderate Buy,’ is based on 2 buy ratings.View TSE:CWEB Price Target & Analyst Ratings Detail GW Pharmaceuticals, Plc. GWPHThe last article in today’s look at cannabis market leaders is also an early entrant to the field, and the only one to trade on the US markets. GW Pharma formed in the UK, in 1998, to conduct research into medical uses of both CBD and THC, the main active compounds in cannabis. Last year, the company received approval for its cannabis-based epilepsy drug, Epidiolex. Sativex, a treatment for symptoms of MS, has been on the markets since 2010.GW’s niche in the cannabis world is a bit unique. It’s not going for the recreational market at all, nor is it interested in the consumer health sector. It is a traditional pharmaceutical company, that saw the potential for cannabis-based prescription medications early on, and is now reaping the benefit of that very early entrance to the field.In its last quarterly report, GW publicized the results of the Epidiolex launch. Writing from Piper Jaffray, Danielle Brill (Track Record & Ratings) said, “GWPH continues to deliver. We think the growth trajectory will continue over the coming quarters given expected EU launch, ongoing dose-titrations, increasing penetration into adult population, transition of remaining expanded access program patients to commercial product, and expansion into new indications.” Her $210 price target on the stock (a 13% boost from her previous target), suggests an upside of 22%.Paul Matteis (Track Record & Ratings), of Stifel, also sees a bright future for the company. Writing of the Epidiolex approval and initial sales, he points out both the forecast-beating profits and management’s prudent words of caution: “GW reported an extremely strong 1Q with $33.5M in Epidiolex sales, consensus was ~$16MM. While the 600%+ q/q rev growth rate was spectacular, management was careful to remind investors that the quarter benefited from ~5 months of pent-up demand and patient-finding efforts.” Matteis gives GWPH a ‘Buy’ rating with a target of $227, or a32% upside from current levels.GW Pharmaceuticals has a unanimous analyst consensus of ‘Strong Buy,’ based on 10 buy ratings. The stock is trading for $170, and the average price target of $219 gives an upside of 28%.View GWPH Price Target & Analyst Ratings DetailFind out more about these four leading cannabis stocks, and many more, with TipRanks’ Stock Comparison Tool.Canopy, Charlotte's Web, Aurora, and GW Pharma in the Stock Comparison Tool
June has been one roller coaster ride for cannabis stocks. First, the FDA reported that CBD be treated like a drug causing cannabis stocks to decline, then a slurry of upgrades caused some cannabis stocks to soar and now the whole industry is rebounding with overall good investor sentiment.Honestly, no surprises for such a volatile industry. This volatility, surprising last-minute news and enormous swings are nothing new for cannabis stocks. Although one stock was particularly interesting. When the FDA reported its ‘findings’ for CBD, GW Pharmaceuticals (GWPH) seemed to explode.From a technical standpoint, GWPH is a very interesting stock. Unlike most of the industry, GWPH is trending positively beyond any normal cannabis stock consolidation. In fact, the stock is looking more like an incredibly bullish long-term buy. Why is GW Pharmaceuticals so interesting? First of all, after the FDA’s ruling on CBD, GWPH stock jumped. Why? Because the company owns one of the only CBD products approved by the FDA for treatment of both childhood-onset forms of epilepsy. The drug itself is called Epidiolex and you’ll be hearing a lot about it in the weeks to come. Having close ties with the FDA is a really good asset to have. Although letting companies have free reign over CBD would be good for everyone, the government is still in charge of consumer safety. Federal bodies like the FDA won’t just back down from controlling weed products or CBD. It’s still going to be a tax, health and legal issue. So don’t expect the FDA to just wipe its hands clean and forgive or forget CBD products.Another important factor is that GW Pharmaceuticals is neither a Canadian or American company. It’s located and licensed in United Kingdom. Why is important? Because the European market is an incredibly valuable future marketplace for many big producers including Canopy and Aurora. Having a stationed and licensed cannabis company in any European country makes it an incredibly valuable proposition for investors. Companies like GW Pharmaceuticals will build resistance within their governments to prevent larger cannabis companies from simply setting up shop in their markets. Depending on how Brexit plays out, the final deal with the EU might either boost GW Pharmaceuticals or restrict its access to Europe. But most likely, some type of free trade agreement will exist between EU states and United Kingdom since trade is such an incredibly valuable part of Europe. Additional, European sentiment towards pot is positive. Most European countries are fairly libral when it comes to legalization and taxation of weed. Remember, pot was legal in parts or Europe way before North America.For investors, GW Pharmaceuticals looks like a great stock. The company itself reported better than expected sales for Epidiolex and announced recently positive results from its phase 3 study of the drug treating another rare type of epilepsy. And overall its been on a run and consolidating in a tight range upwards. It’s also a great stock to diversify away from strictly American and Canadian cannabis market. Looks like a great investment for the future of global cannabis.Analysts seem to agree. The cannabis player stands as a 'Strong Buy' name among Wall Street analysts, according to TipRanks. In the last three months, GWPH has won 10 bullish 'buy' recommendations. With a return potential of nearly 23%, the stock's consensus price target lands at $219.56.To read more on the nitty gritty of what’s going on in the rising cannabis industry, click here. Read more on GWPH: * Medicinal Cannabis Stock GW Pharmaceuticals Could Run Much Higher Over Time * Analysts Have Chosen: GWPH, APHA and CGC Are Top Cannabis Stock Picks More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target
Zynerba (ZYNE) gets a new U.S. patent covering methods of treating autism spectrum disorder with cannabidiol, a key compound of its lead pipeline candidate, Zygel.
No matter what the FDA decides with regard to cannabidiol as a food or beverage additive, it'll have little bearing on consumers or investors.
Last Friday, the U.S. Food and Drug Administration (FDA) held its first public hearing about the safety and regulation of cannabis and cannabis-derived products. At the heart of the hearing were issues of how the FDA should regulate CBD, which has been growing in popularity as both a nutritional supplement and as a patented pharmaceutical ingredient. As Garrett Graff, managing attorney with Denver-based Hoban Law Group, previously told Hemp Business Journal, stakeholders and speculators should not expect any immediate answers.
The Zacks Analyst Blog Highlights: GW Pharmaceuticals, Canopy Growth, Aurora Cannabis and Hexo
Cannabis stocks were mostly lower Monday, as investors digested the first reports from Friday’s regulatory hearing on cannabis and its ingredients and the news that Illinois is legalizing weed for adult recreational use.
Analysts estimate that nearly 65 million Americans have tried CBD and 63% have found it effective. What's more, CBD is a growing industry with sales expected to rise 55% to $648 million in 2019.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older and which is now available by prescription in the U.S. The Company has submitted a regulatory application in Europe for the adjunctive treatment of seizures associated with LGS and Dravet syndrome.
Regarding the lawsuit against the federal government, one of the plaintiffs, Nelson Guerrero, executive director of the Cannabis Cultural Association told Benzinga: “Come fall we will be heard again by the second circuit, and hopefully the DEA will do right by the people with a fair and fast decision.
Cannabis stocks fell Friday, weighed down by the selloff in the broader market after President Donald Trump opened a new front in his trade war, this time with Mexico, and as a key hearing aimed at creating a regulatory framework for CBD kicked off.
Should you put your hard-earned money into these stocks? We detail the investment opportunities, the risks, and regulations in the cannabis space.
Several CBD manufacturers, researchers, farmers and retailers have urged the regulatory authority to allow the use of cannabis.
Cannabis stocks turned lower Thursday, a day ahead of a key hearing by the U.S. Food and Drug Administration, seeking information and data on the substance and its ingredients with the aim of creating a regulatory framework for CBD.
It's no secret that marijuana and Cannabidiol (CBD) stocks have been on fire. But you don't have to go with the flock of growers, packaging companies and hemp derivative companies to play the trend, observes growth stock expert Mike Cintolo, editor of Cabot Top Ten Trader.
Marijuana stocks are hot these days. And there's a good reason why. As Canada and several U.S. states have legalized cannabis for both recreational and medical use, the sector has plenty of potential. In fact, some analysts think that by 2025, the cannabis sector could grow to be a $146 billion industry. That means it will grow at a compound annual growth rate (CAGR) of 34% from today. Naturally, many start-ups and early stage marijuana stocks have jumped into the fray to take advantage of that growth.But the truth is, many of the winners in the cannabis sector are already here and cooking. Thanks to their really early mover status, growing moats and big deals, several marijuana stocks are already emerging as winners in the surging industry. The reality is, investors may not need to dabble in penny stocks and up-listed pot stocks. The only three marijuana stocks you need to own are already here. * 7 Stocks to Buy for June With that said, here are the three real winners in the cannabis sector.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Marijuana Stocks to Buy: GW Pharmaceuticals PLC- ADR (GWPH)Source: Shutterstock One of the biggest uses of cannabis continues to be for medicinal purposes. There are plenty of marijuana stocks out there looking at using the power of cannabis to cure and treat various ailments. But only GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has an approval under its belt.Last summer, GWPH received approval for its cannabinoid drug Epidiolex, which is used to treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. An approval is an impressive feat for any biotech firm, let alone for marijuana stocks. The drug was officially launched in November and it was off to the races for GWPH stock. Year-to-date, shares are now up around 86%.And it looks like the gains could keep coming for GW Pharmaceuticals.Prescriptions of Epidiolex have surged in its first quarter of issuance and physicians seem to love the medication. GWPH stock generated more than $33.5 million in sales of the drug during the first quarter. Meanwhile, the biotech has been able to pivot the drug successfully in other trials. A phase III trial for Epidiolex in treating seizures associated with tuberous sclerosis complex has proved to be amazing so far. All in all, GW Pharmaceuticals may have a true blockbuster on its hands. The end market for treating epilepsy is just that massive and the firm should be able to pivot its medicine accordingly.For investors looking at marijuana stocks in the medical sector, GWPH is a sure thing. Canopy Growth Corporation (CGC)Source: Shutterstock Given that it's a budding industry, those marijuana stocks with big partnerships are more likely to succeed these days. And no one has been racking up deals faster and better than leading cannabis firm Canopy Growth Corporation (NYSE:CGC).First of all, CGC is a massive grower of pot. This scale provides it plenty of potential to serve other, larger, more established corporations. And that's just what Canopy has done. The firm's $4 billion deal with beverage and spirit maker Constellation Brands (NYSE:STZ ) set the industry standard. The duo has already started working on cannabis-infused drinks as well as edibles and other consumable products.The deal also provided CGC plenty of cash to grow and make acquisitions of its own. CGC has smartly moved into the pet care arena via a deal with Martha Stewart. Meanwhile, a buyout of U.S.-focused Acreage Holdings will give it instant access to pot here at home when it legalized for recreational use. * 7 Utility Stocks to Trust for Retirement With these major partnerships in tow, CGC has already cemented itself as the top player among the marijuana stocks. It has the scale, partnerships and cash available to actually make the cannabis dream a reality. For investors, it may be the only pot stock you need. Tilray (TLRY)Source: Shutterstock If Canopy is a play on recreational marijuana use, than leading cannabis stock Tilray (NASDAQ:TLRY) could be a play on the growing medical use around the world. Medical marijuana and cannabis treatment demand has already begun to surge in many locations. That's because doctors look for alternatives to addictive opioids for pain relief. TLRY is on the leading edge of that trend, as one of the largest medical dispensaries around.And it's only getting bigger.TLRY has partnered with major pharmaceutical giant Novartis (NYSE:NVS ). Through its Sandoz division, TRLY is able to tap into one of the largest pharmaceutical distribution networks in the world as well as provide guidance on how to navigate these various regulatory environments. Having a Novartis stamp on your medical products certainly can go a long way with doctors and consumers using medical marijuana. As a result, Tilray has been able to export its weed to far off places like the U.K., Australia, New Zealand and parts of South America.All of this has shown up in the firm's torrid revenue growth. Last quarter, sales at Tilray surged a blistering 195%. With its focus on being the global leader and having a major pharma stock in its corner, further sales and profits could be had.In the end, TLRY could be the best of the marijuana stocks when it comes to being a major medical player.At the time of writing, Aaron Levitt did not have a position in any of the stocks mentioned. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy for June * 7 Stocks to Buy From One of America's Best Pension Funds * 4 Consumer Staples Stocks for Both Income and Growth Compare Brokers The post The Only 3 Marijuana Stocks You Need to Own appeared first on InvestorPlace.
Cannabis stocks were mostly higher Tuesday, as investors braced for a Friday hearing by the U.S. Food and Drug Administration on how to regulate cannabis and its popular ingredient, CBD.
If you are looking to invest in cannabis stocks, you may want to take a closer look at cannabis biotechs in particular. Several cannabis biotech firms are generating significant Street support- and for good reason as you will see below. To pinpoint the most compelling cannabis biotech stocks out there, we used TipRanks' data to pull up relevant biotechs with a 'Strong Buy' Street consensus. That's based on all the ratings received from analysts over the last three months. In fact, all these three stocks actually score 100% Street support- so no hold or sell ratings here. Let's take a closer look now at which 3 stocks make the grade, and why: GW Pharmaceuticals (GWPH – Research Report)British-based biopharma GWPH is one of the more well-known cannabis biotech stocks. Shares have put on a remarkable sprint for the beginning of 2019. Year-to-date we are now looking at gains of 88%. And the company’s recent earnings report indicates that plenty of growth lies ahead. In June 2018, the company’s lead cannabinoid drug Epidiolex received FDA approval for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome. Following DEA re-scheduling, Epidiolex was launched on November 1.So far the launch has proved a remarkable success. For the first quarter, GW reported $33.5MM in Epidiolex revenue during its first full quarter on the market, well ahead of consensus ($15.9MM). But even more importantly, the company also revealed positive trial data for tuberous sclerosis complex (TSC). Specifically, GW announced that Epidiolex's Phase III trial in patients with seizures associated with tuberous sclerosis complex (TSC) met its primary endpoint with a high degree of statistical significance.The primary endpoint was the percent change from baseline in seizure frequency during the treatment period. At baseline, enrolled patients (average age of 14 years old) experienced a median of 57 seizures per month. After 16 weeks of treatment, patients in the 25 mg/kg/day cohort experienced an impressive 48.6% reduction in seizures relative to baseline.“1Q Snapshot \- A Strong Launch and Positive TSC Data Rolled Into a Joint Announcement for a Double Dose of Good News” cheered JP Morgan’s Cory Kasimov following the report. The analyst continued: “We’re not sure how GWPH’s 1Q19 report could have gone much better with Epidiolex doubling consensus in its first full quarter of sales… only to be one-upped by concurrent positive Phase 3 data in TSC.”As a result he believes Epidiolex is on track to come in north of $150M in its first full year, easily exceeding Street expectations. “The bottom line is that estimates need to come up, perhaps meaningfully. Furthermore, with another positive – and clean – phase 3 dataset in hand, there could be upward bias to longer term off label epilepsy sales, which offers a major upside lever in our model” concludes Kasimov. He reiterated his buy rating while ramping up his price target from $180 to $215. Unsurprisingly, he wasn’t the only analyst singing GWPH’s praises. “Based on Epidiolex's trajectory and the positive TSC data today we are increasing our DCF-based price target from $175 to $200. We continue to think that GW is undervalued” commented Cowen & Co’s Phil Nadeau. At the same time Oppenheimer’s Esther Rajavelu took a step further by upgrading GWPH from Hold to Buy. She also upped her price target from $164 to a Street-high $234 (27% upside). “While we await detailed data that may be shared at a medical conference, we update our probability of approval of the sNDA [supplemental new drug application] for TSC to 87% from 41% (filing expected in 4Q)” she explained. Overall GWPH has a very bullish outlook from the Street, with ten analysts publishing recent buy ratings on the stock. Their average analyst price target stands at $220- indicating upside potential of 20%. View GWPH Price Target & Analyst Ratings Detail Zynerba Pharmaceuticals Inc (ZYNE – Research Report)Zynerba is developing next-generation cannabinoid gels to help treat patients affected by rare neuropsychiatric conditions. The company is generating a significant buzz, with shares exploding over 340% year-to-date! So what’s behind the stock’s meteoric rise?Its lead drug candidate Zygel is a unique permeation-enhanced CBD transdermal gel. By delivering drugs through the skin and directly into the circulatory system, Zygel offers several advantages over oral medication. Most notably, transdermal delivery results in fewer gastrointestinal side effects, and avoidance of first-pass liver metabolism. This potentially enables lower dosage levels of active pharmaceutical ingredients and rapid, reliable absorption. Encouragingly, Zynerba announced earlier this month that the FDA has granted a Fast Track designation on Zygel for the treatment of behavioral problems associated with Fragile X syndrome (FXS). “With this designation, the company gains easier access to the FDA throughout the development process and most importantly, in our view, eligibility for Priority Review, which shortens the review time to six months” explains Ladenburg’s Michael Higgins. He anticipates Zygel’s NDA (new drug application filing) will take place in 1H20, leading to approval in 2H20. And with an eye on the future, Higgins reiterates his buy rating on ZYNE with a $26 price target (97% upside potential). While data since the summer of 2018 has been light, multiple major data readouts are comping up near-term- generating the recent rally in prices. “We continue to believe the stock could still double from its current level, driven by a data-rich 2H’19” the analyst tells investors. Upcoming data readouts include Phase 2 data from BELIEVE 1, evaluating Zygel’s anti-epileptic activity, and data from the FXS pivotal CONNECT-FX trail. “Given the unprecedented, profound and sustained benefits across multiple behavioral problems in the open-label Phase 2 (FAB-C), plus Zygel’s good tolerability, we again expect this trial to be successful” writes Higgins. Plus the catalysts should continue into 1H20 when data is expected for two new indications (autism spectrum disorder (ASD) and 22q11.2 deletion syndrome). Analysts are clearly feeling the heat- this is a stock with five recent back-to-back buy ratings and an average analyst price target of $23 (79% upside potential). View ZYNE Price Target & Analyst Ratings Detail Cara Therapeutics Inc (CARA – Research Report)Cara Therapeutics is a biotech focusing on developing products for better pruritus (i.e. severe itching- one of the most common dermatological complaints) and pain management. Right now, all eyes are squarely set on the imminent US Phase 3 data for IV Korsuva. This is Cara’s novel kappa opioid receptor agonist to treat chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients- where there is currently no effective treatment and minimal competitive development.Indeed top-rated Cantor Fitzgerald analyst Charles Duncan has just hosted a call with a key opinion leader (KOL) to discuss the outlook for Korsuva. In this case the KOL is a physician with expertise in chronic kidney disease associated pruritus (CKD-aP), making his insights particularly valuable. Overall, the KOL stated that, in his 25 years as a practicing nephrologist, he has seen little in drug development move the needle in CKD-aP (except the P2 data from KORSUVA), underscoring the need for new medications.“As a result of this recent due diligence, we have enhanced conviction about the P3 study readouts and potential for KORSUVA to usher-in a paradigm shift and a new SoC [standard of care] for this high-burden symptom of disease” Duncan concluded. He expects the data readout to come early June, and is upbeat about the drug's prospects. “We remain confident in positive results based on statistically significant Phase 2b results with much lower powering and shorter treatment duration” the analyst tells investors. Meanwhile, the second global Phase 3, KALM-2, is enrolling and management expects data in “2H19” (i.e. around 4Q). "Assuming KALM-1 is positive, we’ll also be optimistic for KALM-2", says the analyst. He reiterated his buy rating with a $27 price target, writing ‘Now is the time to scratch the itch.’ Given the stock is currently only trading at $18, the price target translates into sizable upside potential of over 50%. Bear in mind shares are already soaring 39% year-to-date. As we can see here, that's on top of six recent buy ratings from the Street:View CARA Price Target & Analyst Ratings Detail Enjoy Research Reports on the Stocks in this Article:Cara Therapeutics Inc (CARA) Research ReportGW Pharmaceuticals (GWPH) Research ReportZynerba Pharmaceuticals Inc (ZYNE) Research Report
Yahoo Finance dives deep into the cannabis industry's rapid expansion and where investors are looking for growth in the space. Join reporters Zack Guzman, Alexis Keenan Weed and Emily McCormick as they interview leaders of some of the biggest cannabis companies and report on what's next for the sector.